Introduction
Vertebrate genome contains 3-5 members of the heat shock transcription factor (HSF) family (for reviews, see Pirkkala et al., 2001; Akerfelt et al., 2007) . Within this family, HSF1 and HSF2 possess closely related DNAbinding domains, but they exhibit some slight differences in heat shock element (HSE) recognition (Kroeger and Morimoto, 1994; Yamamoto et al., 2009) , suggesting that both factors control different set of genes. HSF1 represents the archetypal stress transcription factor, rapidly activated by a large variety of proteotoxic stimuli. It regulates the stress-inducible expression of heat shock proteins (HSPs) but also controls numerous other genes as shown by the transcriptome analysis (Trinklein et al., 2004) . Recently, it was shown that HSF1, by favoring cellular adaptation and survival in response to environmental stress, also enhances oncogenic transformation (Dai et al., 2007) . In comparison with HSF1, HSF2 is a less efficient transcriptional activator and appears to be differently responsive to stimuli (Sistonen et al., 1992) . However, inhibition of the proteasome activates both HSF1 and HSF2 (Kawazoe et al., 1998) . Proteasome inhibition leads to the accumulation of misfolded proteins and consequently induces expression of all the major HSPs (Bush et al., 1997) , but Pirkkala et al. (2000) clearly showed that HSF1, but not HSF2, has a key role in this induction. Nevertheless, to add to the complexity of this proteotoxic response, our group showed that an HSF1/HSF2 heterocomplex was present on the promoter of the chaperone gene clusterin, following proteasome inhibition (Loison et al., 2006) . The existence of the HSF1/ HSF2 heterotrimer was recently confirmed (Sandqvist et al., 2009) and it was shown that HSF2 can act as a modulator of HSF1 activity in response to proteotoxic insults (Ostling et al., 2007) . Hence, the respective roles of HSF1 and HSF2 remain unclear when cells are exposed to proteasome inhibitors.
The proteasome/ubiquitin system constitutes the major pathway for the regulated degradation of intracellular proteins. The proteasome holoenzyme is a large multi-subunit complex composed of a 20S proteolytic core particle associated with one or two 19S regulatory particles (Pickart and Cohen, 2004 ). The 20S core particle is a cylindrical structure made up of four heteromeric rings. The two outer rings are composed of seven different a subunits (named a1 to a7), whereas the two inner rings are composed of seven different b subunits (b1-b7) and form the catalytic chamber. Although these subunits are evolutionary related and similarly conserved, only b1, b2 and b5 possess proteolytic properties. The 19S regulatory particle comprises approximately 18 distinct subunits that form a lid controlling the access to the catalytic core particle. Proteins destined to be degraded by proteasome must be conjugated to multi-ubiquitin chain for recognition by the 19S regulatory particle. Dysfunction of the proteasome pathway can lead to many disorders, including cancers and neurodegenerative diseases (Paul, 2008) . Proteasome is crucial for the regulation of cell cycle and apoptosis and its specific inhibition by molecules has emerged as a promising strategy to treat cancers (Nencioni et al., 2007) . For example, bortezomib (also known as PS-341 or Velcade) is the first proteasome inhibitor used in the treatment of multiple myeloma (Twombly, 2003) . In addition, proteasome inhibition may modulate many other transcriptional events (Muratani and Tansey, 2003) and the activity of the stress-related transcription factors, such as p53 and HSFs.
To determine the contribution of HSF2 versus HSF1 in cell response to proteasome inhibitors, we used immortalized mouse embryonic fibroblasts (iMEFs) derived from wild-type (WT), Hsf1 and/or Hsf2 knockout mice (McMillan et al., 1998 (McMillan et al., , 2002 . We found that both factors are essential for the cell viability but have distinct actions: as previously shown, HSF1 is required in the induction of pro-survival HSP expression and, in contrast, HSF2 is involved in the regulation of proteasome subunit expression.
Results
Proteasome inhibition is severely toxic for HSF1-and/or HSF2-deficient cells To determine the specific contributions of HSF1 and HSF2 to the cellular response to proteasome inhibition, we first examined the cytotoxic effect of two proteasome inhibitors: the peptide aldehyde MG132, a reversible inhibitor, and the peptide epoxyketone epoxomicin, an irreversible inhibitor. To assess the viability of iMEF cells, we used the quantitative colorimetric 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) test as cytotoxicity assay and established concentrationeffect curves after a 16 h treatment. With high concentrations of MG132 (830 nM) or epoxomicin (250 nM), Hsf1
À/À iMEFs were significantly more sensitive to these proteasome inhibitors than WT cells (Student's t-test, Po0.05 and Po0.001, respectively) ( Figures 1a and b, respectively) . By comparison, we treated cells with thapsigargin that induces a proteotoxic stress specific to the endoplasmic reticulum without affecting proteasome activity and without activating HSF. In contrast to proteasome inhibition, thapsigargin treatment had the same effect on the four cell lines. These data clearly showed that the higher sensitivity of HSF1-and HSF2-deficient cells was specific to proteasome switch-off and was not a direct consequence of a general alteration of stress response in these knockout cells (Figure 1c) .
To evaluate whether the decline of MTT values after proteasome inhibition was due to an antiproliferative or a cytotoxic effect, we conducted a flow cytometric analysis of cellular viability. The WT or HSF-deficient iMEFs were treated for 16 h with 1 mM of MG132, and then apoptotic levels were determined by staining with annexin V-fluorescein isothiocyanate and 7-aminoactinomycin D (Figure 1d and Supplementary Figure S1 ). Mortality of all the cell lines was increased in MG132-treated samples, and apoptosis level in HSF-deficient cells was found to be twofold higher compared with WT cells. These data revealed that both factors, HSF1 and HSF2, are critical for cell survival when proteasome is inhibited.
HSP induction is differently affected in Hsf1
À/À and Hsf2 À/À iMEFs HSPs are important chaperones induced by proteotoxic stress which contribute to cell death resistance (Beere, 2005) . Thus we analyzed the inducible expression of two HSPs: HSP70 and HSP25. Messenger RNA levels of Hsp25 and Hsp70 in WT, HSF1 and/or HSF2-deficient iMEFs were compared in the absence or presence of MG132 (Figures 2a and b) . After MG132 exposure, only iMEFs expressing HSF1 (either WT or Hsf2 À/À ) were able to exhibit a strong induced expression of both chaperones, whereas iMEFs deficient in HSF1 (Hsf1 ). Moreover, HSF2-depleted cells show higher levels of HSP25 and HSP70 than those observed in WT iMEFs, which could be explained by a lower level of protein degradation and thus an increase in the protein's halflife in those Hsf2 À/À cell lines. Hence, it was unlikely that the high sensitivity of Hsf2 À/À cells to proteasome inhibition could be explained by the lack of HSPs. This suggested that another mechanism should be involved.
Proteasome activity is decreased in Hsf2
À/À iMEFs To test the possibility that proteasome function would be natively affected, an in vitro assay based on the measurement of the chymotrypsin-like activity of proteasome present in crude protein extract was first used. Second, the proteasome activity at the cellular level was evaluated, by setting up an assay based on the degradation of a proteasome-targeted protein.
A fluorescent proteasome substrate (Z-LLVY-AMC) was incubated with cellular extracts from the different iMEF cell lines. This peptide was hydrolyzed by the chymotrypsin-like activity of proteasome releasing the fluorophore that could be assessed with a spectrofluorimeter (Figure 3a) . À/À cells (0.63±0.14) was less striking but still significant. To ascertain that the measured fluorescence was due to proteasome activity, crude extracts were incubated with HSF2-dependent expression of proteasome subunits S Lecomte et al the peptide and 10 mM of MG132 and no fluorescence could be measured, indicating that this inhibitor clearly abolished the previously assessed activity.
To confirm in vivo this observation at the cellular level, expression vector coding for the fusion protein uncleavable ubiquitin-green fluorescent protein (Ubi-GFP) was transfected in iMEFs. The mutated non-cleavable ubiquitin moiety within the fusion protein serves as template to poly-ubiquitination, which is addressed to the proteasome for degradation. Thus, intracellular accumulation of the unstable Ubi-GFP requires partial or total inhibition of the proteasome/ Figure 1 Increased vulnerability to proteasome inhibition in HSF-deficient cells. Dose-response curves for cell viability assessment by MTT assay were prepared using immortalized mouse embryonic fibroblasts (iMEFs) exposed to proteasome inhibitors (a, MG132 and b, epoxomicin) or endoplasmic reticulum stressor (c, thapsigargin). WT (black diamond), Hsf1 À/À (white square), Hsf2 À/À (white triangle) and Hsf1 À/À & Hsf2 À/À (white circle) iMEFs were incubated for 16 h with DMSO (Cont) or indicated concentrations of the drugs before being subjected to MTT assay. Results are expressed in percentage of survival compared with DMSO control (Student's t-test: each knockout cell compared with WT cells. *Po0.05, ***Po0.001). To confirm that decrease of survival was due to apoptosis, cells were treated with 1 mM of MG132 for 16 h and apoptosis was assessed by flow cytometry using annexin V-fluorescein isothiocyanate and 7-aminoactinomycin D (d). Results were expressed in percentage of cell death for DMSO (cont) and MG132 treated cells. Data are the means for three to four independent experiments ± s.e.m. HSF2-dependent expression of proteasome subunits S Lecomte et al ubiquitin system. The Ubi-GFP expression vector was co-transfected with a plasmid coding for enhanced GFP (EGFP) as internal control to evaluate the difference of transfection efficiencies between the iMEF cell lines. Then, the protein levels of GFP were probed by immunoblotting, using the same antibody ( Figure 3b ). In all cell lines (except the double knockout iMEFs), the EGFP control is highly expressed, showing that the transfections were equally efficient. We found that in WT and Hsf1 À/À cells, the Ubi-GFP-specific bands were not visible in untreated cells whereas it became slightly detectable when cells were incubated with 1 mM of MG132. These data showed that Ubi-GFP was efficiently targeted to proteasomal degradation and showed that exposure to 1 mM MG132 could not totally block the intracellular proteasome activity. By contrast, Ubi-GFP was significantly more stable in cells deficient in HSF2 (Hsf2
), especially after MG132 treatment (Figure 3b , lanes 6 and 8, respectively). This indicated that HSF2-deficient cells exhibited a reduced proteasome activity either due to functional defect or due to reduced amount of the proteasome machinery in comparison with WT.
Partial but significant depletion of the ubiquitinproteasome machinery in Hsf2 À/À iMEFs To determine whether the decrease of proteasome activity was linked to reduced level of proteasome subunit expression, 10 subunits were selected (5 located in the 20S particle and 5 located in the 19S particle- Table 1 ) based on the work of Kruger's team about proteasome expression in response to proteasome inhibition (Meiners et al., 2003) and the level of transcripts was analyzed by real-time polymerase chain reaction (PCR) analysis. The expression level of two ubiquitin genes (Ubb and Ubc) was also analyzed. As summarized in Table 1 , a decreased expression was observed in the absence of HSF1 for some proteasome subunits and for Ubb and Ubc, but at a lower level than observed in HSF2-deficient cells. In fact, the level of majority of the 20S and 19S subunits, similar to the two ubiquitin genes, decreased by a factor of two-or threefold in HSF2-deficient cells. However, mRNA levels of two subunits, Psmb4 and Psmc5, were unchanged in HSF-deleted cells compared with WT, suggesting that all constitutive subunits are not regulated in the same way. In addition, it is interesting to note that the level of the b5 catalytic subunit (Psmb5) was significantly lower in Hsf2 À/À and Hsf1 (Table 1 and Figure 4a ), which is consistent with the decrease in proteasome activity measured in these cells (Figure 3a ). To ascertain that this decrease of expression was due to the lack of HSF2, we stably transfected Hsf2 À/À iMEFs with a plasmid coding for HSF2 or a control vector (Figure 4c and Supplementary Figure S2 ). Reintroduction of HSF2 allowed a rescue of Psmb5 expression, which was 2-3-fold higher in transfected cells with Hsf2 vector in comparison with the empty vector.
Increased stability of p53 in HSF2-depleted cells As shown in Figure 4b , Psmd10 or gankyrin, an oncogene overexpressed in human hepatic cancers (Higashitsuji et al., 2000) , was 2-4-fold down-regulated in HSF2-deficient iMEFs and its expression was totally rescued when cells were transfected with Hsf2 vector (Figure 4d ). As gankyrin is also known to interact with the MDM2 ubiquitin ligase and to have a pivotal role in controlling the level of p53 by proteasomal degradation (Higashitsuji et al., 2005) , we wanted to determine whether the lower level of gankyrin affects intracellular p53 concentration. Using untreated cells, in immunoblot assay, endogenous p53 was hardly visible in WT and Hsf1 À/À iMEFs, whereas it was dramatically increased in both Hsf2
À/À and Hsf1 (Figure 5a ). Real-time PCR analysis revealed that there was no significantly increased level of p53 transcripts in cell lines that exhibited higher p53 protein content, suggesting that this p53 upregulation in HSF2-deficient cells was due to protein stabilization (Figure 5b ). Finally, a pulse-chase experiment using p53 antibody was performed to assess the p53 half-life in our model. As shown in Figure 5c , endogenous p53 in WT iMEFs exhibited a very short half-life (less than 1 h). In Hsf1 HSF2-dependent expression of proteasome subunits S Lecomte et al iMEFs the p53 half-life was slightly longer than in WT cells as previously described (Jin et al., 2009) . p53 was yet detected after 2 h of chase. This result was in accordance with the decrease in proteasome activity observed in HSF1-deleted cells. In sharp contrast with this modest increased stability, p53 was dramatically stabilized to a half-life of more than 9 h, in Hsf2 À/À cells. To confirm this stabilization, p53 immunoblotting was performed in primary MEF from WT, Hsf1
À/À and/or Hsf2 À/À mice. In those cells, the basal endogenous p53 was not detectable (Figure 5d ). In contrast, when cells were treated with 1 mM of MG132, p53 was slightly increased in WT and Hsf1 À/À MEFs, whereas a strong accumulation was detectable in Hsf2 À/À and Hsf1 Abbreviations: HSF, heat shock factor; iMEF, immortalized mouse embryonic fibroblasts; WT, wild type. RNA level of five subunits of the 20S particle, five subunits of the 19S particle, and ubiquitin B and C were measured by real-time PCR and normalized using three reference genes, Gapdh, Hprt1 and Tbp. Results are expressed as relative value to WT. Data are the mean for four independent experiments ± s.d. Figure 4 Transcript levels of proteasome subunits in HSF-deficient iMEFs and HSF2-rescued iMEFs. WT or HSF-deficient iMEFs (Hsf1 À/À , Hsf2 À/À and Hsf1 À/À & Hsf2 À/À ) were plated and total RNA was extracted the day after. Relative basal expression of two proteasomal subunits Psmb5 (a) and Psmd10 (b) were assessed by real-time PCR and normalized using three reference genes, Gapdh, Hprt1 and Tbp. Transcript levels in HSF-deficient cells were presented as relative value to WT. Data are the means for four independent experiments ± s.e.m. (Student's t-test compared with WT cells. *Po0.05, **Po0.01, ***Po0.001). For rescue experiments cells were transfected with PCR3.1 as control vector (white histogram) or PCR3.1 expressing HSF2 (black histogram). Three independent stable clones of each transfection were selected (cl 1, 2, 3 for control vector transfection and cl 4, 5, 6 for HSF2 transfection). Psmb5 (c) and Psmd10 (d) expression levels were measured by real-time PCR in each clone and in WT cells (gray histogram). Transcript levels in each stable clone and in WT cells were presented as relative value to PCR3.1 cl 1 for three independent experiments±s.e.m. Data were analyzed with qBase software.
HSF2-dependent expression of proteasome subunits S Lecomte et al

Discussion
Proteasome inhibition causes an accumulation of altered proteins, generating a proteotoxic stress, which was shown to simultaneously activate both HSF1 and HSF2 (Kawazoe et al., 1998) . Nevertheless, the respective roles of HSF1 and HSF2 remained unclear. We took advantage of genetically modified cells to further clarify the specific function of each factor in the cellular response to such a stress. We found that HSF1 and HSF2 were both critical for the resistance to proteasome inhibition. However, HSF1 and HSF2 are involved in different mechanisms. HSF1 deficiency dramatically prevented the induced expression of Hsp25 and Hsp70 after proteotoxic stress. This was in agreement with previous works showing that HSF1 is the major factor involved in proteotoxic response and that it could not be compensated by HSF2 alone (Pirkkala et al., 2000) . As HSP25 and HSP70 promote cellular survival by preventing protein aggregation, facilitating refolding and directly inhibiting apoptotic signaling (Beere et al., 2000; Bruey et al., 2000) , Hsf1
À/À cells lacked an important protective mechanism, which could explain the observed reduction in cell survival. In contrast to Hsf1 deletion, Hsf2 deletion did not prevent induction of Hsp25 and Hsp70 expression. Thus, the high expression of protective HSP in Hsf2 À/À iMEFs led us to conclude that HSF2 and cell sensitivity to proteasome inhibition were linked by a different mechanism. According to this hypothesis, we were interested in proteasome subunit expression and found that it was particularly affected in Hsf2 À/À cells. Little is known about the regulation of basal expression of mammalian proteasome subunits. Recently, one study suggested that each type of proteasome subunit could be regulated by common unknown transcription factors (Sato et al., 2009) . It was found that inactivation of HSF1 does not alter proteasome expression (Taylor et al., 2005) and our data are in accordance with this report as we show that Hsf1 À/À iMEFs exhibit a slight but not significant decrease in proteasome subunit expression. However, this slight decrease could be explained by the interdependence between HSF2 and HSF1 (Loison et al., 2006; Sandqvist et al., 2009) . Thus, one could hypothesize that the lack of HSF1 would affect HSF2 binding and consequently reduce HSF2 activity.
Currently, we do not know whether HSF2 regulates proteasome subunit expression indirectly or by direct binding to the promoters of the corresponding genes. By in silico analysis we searched for the presence of HSE within genes encoding proteasome subunits and found that the majority of those genes possess putative degenerated HSEs. For example, the gankyrin gene À/À and/or Hsf2 À/À animals were treated with DMSO (cont) or with 1 mM of MG132 for 16 h. Protein extracts were prepared and p53 western blotting was realized. b-Actin was used as loading control.
HSF2-dependent expression of proteasome subunits S Lecomte et al contains a conserved HSE in its first intron. This sequence was able to bind HSF in electrophoretic mobility shift assay, but we hardly detected in vivo HSF2 binding by chromatin immunoprecipitation assay (data not shown). The difficulty in detecting HSF2 bound to gankyrin HSE could be explained by the fact that this interaction could be very transient. Recently, HSF2 was found to ephemerally bind to Hsp promoters during mitosis and that interaction favored the basal expression of Hsps (Xing et al., 2005; Wilkerson et al., 2007) . Therefore, it is possible that the role of HSF2 in bookmarking that maintains an open chromatin at the promoters of certain genes entails the constitutive expression level of proteasome subunits. To test this hypothesis, formaldehyde-assisted isolation of regulated element assay was performed (Supplementary Figure S3) , which showed that chromatin was more compacted at the gankyrin transcription start site in HSF-deficient cells than in WT cells. However, another mechanism described in yeast could be implicated. An indirect transcriptional network involving HSF and RPN4 was shown (Hahn et al., 2006) . This latter protein corresponds to the main transcription factor implied in the expression of yeast proteasome subunits, but no mammalian homolog has been described to date.
The decreased expression of proteasome subunits has consequence for cell physiology. Alteration of proteasome activity has been implicated in the pathogenesis of cancers (Schwartz and Ciechanover, 1999) and in some cells, a clear relationship has been established between increased expression of proteasome and proliferation or resistance to apoptosis (Fuchs et al., 2008) . We found that decrease of catalytic subunit b5 and gankyrin in HSF2-depleted cells was accompanied by p53 stabilization. It would be interesting to determine whether reintroduction of gankyrin in Hsf2 À/À iMEF could restore the level of p53, knowing that it was already shown that gankyrin overexpression accelerates the degradation of p53 in various cell models, including MEF (Higashitsuji et al., 2005) . Mivechi's group described a mechanism linking HSF1 deficiency and p53 stabilization (Homma et al., 2007; Jin et al., 2009) . Our study confirms a role for HSF1 in the regulation of p53, with a slight stabilization of this protein in pulse-chase experiment compared with WT cells. However, our work completes the mechanism by introducing HSF2 as a new actor. The iMEFs used in this study have been immortalized with T antigen of SV40 virus that is known to bind to p53 and block its transcriptional activity (Pipas and Levine, 2001) , which could permit its stabilization in our model. However, our results (p53 stabilization) were confirmed by p53 immunoblot in primary MEFs. Furthermore, it was found that SV40 transformation does not affect the protein control machinery (Cantalupo et al., 2009) , which emphasizes that the decrease in ubiquitin-proteasome system expression is related to the loss of Hsf2 gene confirmed by HSF2 rescue.
Development of inhibitors of both HSF1 and HSF2 could be a valuable approach to increase the effectiveness of cancer therapy. By blocking HSF1, it is possible to alter the adaptive transcriptional response that allows the expression of anti-apoptotic chaperones (Zaarur et al., 2006) . Therapeutic use of proteasome inhibitors remains limited because of the selection of resistant cells. It was found that bortezomib-adapted cells showed increased expression of b5 and b2 proteasome subunits (Oerlemans et al., 2008; Ru¨ckrich et al., 2009 ), and we found that one of these subunits was underexpressed in the absence of HSF2. Moreover, by blocking HSF2, the level of intracellular proteasome is expected to decrease and potentially to increase the sensitivity to proteasome inhibition, even in resistant clones. Recently, a close correlation was shown between expression levels of proteasome subunits, their enzymatic activity and the sensitivity of cells to proteasome inhibitor (Busse et al., 2008) . Finally, a decrease of gankyrin level in Hsf2-blocked cells would permit overexpression of p53 that will in turn participate in the apoptosis of treated cells.
In conclusion, our work in iMEFs brought new insights into the respective roles of HSF1 and HSF2, the most abundantly expressed HSF in organisms. Beyond these fundamental interests in a better understanding of the transcription factor, the data presented here confirm that HSF1 and now HSF2 could be targeted with benefits in cancer therapy.
Materials and methods
Cell culture
Mouse embryonic fibroblasts wild type (WT), deleted for HSF1 (Hsf1 ) were isolated from knockout mice (McMillan et al., 1998 (McMillan et al., , 2002 and were immortalized using SV40T antigen by Dr V Mezger (UMR CNRS 7216, Paris, France). Cells were maintained in Dulbecco's modified Eagle's medium (DMEM) 4500 mg/l glucose (Gibco, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Biowest, Nuaille, France), 4 mM L-glutamine, non-essential amino acids, 100 U/ml penicillin and 100 mg/ml streptomycin (Gibco). All cells were grown at 37 1C under 5% CO 2 .
For rescue experiments Hsf2 À/À iMEFs were stably transfected with a plasmid coding for Hsf2a, and HSF2 expression was confirmed by RT-PCR and HSF2 immunoblotting in each selected clone (Supplementary Figure S2) .
Plasmid constructs and transfection
A Ubi-GFP was previously used to quantify ubiquitinproteasome-dependent proteolysis in living cells (Dantuma et al., 2000) . For this purpose, the DNA fragment from the pDG268 plasmid (kindly provided by Dr D Gray, University of Ottawa, Ottawa, Ontario, Canada), encoding an ubiquitin-EGFP fusion protein (Tsirigotis et al., 2001) , was transferred into the pCDNA3 expression vector (Invitrogen Life Science, Carlsbad, CA, USA). Then, the carboxy-terminal glycine in ubiquitin was converted to a valine using the site-directed mutagenesis kit QuickChange (Stratagene, Santa Clara, CA, USA), to block cleavage of the ubiquitin moiety by cellular deubiquitinases and thus render the entire fusion prone to degradation by the ubiquitin-proteasome system. The vector coding for non-cleavable Ubi-GFP was co-transfected with a plasmid coding for EGFP (pEGFP-C3, Clontech, Mountain View, CA, USA), as internal control of transfection efficiency.
All transfections were performed with JetPEI (Polyplus Transfection, Illkirch, France), according to the manufacturer's instructions. Cells were harvested after 24 h of transient expression and 7 h of treatment with dimethyl sulfoxide (DMSO) or 1 mM of MG132 (Biomol, Plymouth Meeting, PA, USA). The relative quantity of these two GFP proteins was assessed by immunoblotting using anti-GFP antibodies (Invitrogen Life Science).
Cell toxicity assay (MTT assay) WT, Hsf1
, and Hsf1 À/À & Hsf2 À/À iMEFs were spread in 96-well plate and were treated with increasing doses of proteasome inhibitors epoxomicin (Sigma Aldrich, St Louis, MO, USA), MG132 (Biomol) or with thapsigargin (Sigma Aldrich), an inductor of endoplasmic reticulum stress. Cells were treated with the indicated concentration for 16 h. Following treatment, MTT (Sigma Aldrich) was added to cells at a final concentration of 0.5 mg/ml. Cells were incubated for 3 h at 37 1C under 5% CO 2 . The medium was then discarded and formazan crystals were dissolved in 100 ml of isopropanol with 0.1% sodium dodecyl sulfate and 0.05 N HCl for 1 h at obscurity. Absorbance was read at 570 nm and results were expressed as percentage of untreated cells.
Real-time PCR analysis
One million cells for each iMEF line were plated into a 10-cm plate and harvested after 24 h of culture. Total RNAs were extracted with trizol reagent (Invitrogen Life Science) according to the manufacturer's procedure. Then 5 mg of RNA were retrotranscribed using M-MLV RT (Invitrogen Life Science). Real-time PCR was performed using 12.5 ng of cDNA, 300 nM of primers (referred to the Supplementary Data) and 1 Â SYBRGreen, on MiniOpticon Real Time PCR (Bio-Rad, Hercules, CA, USA). Amplification of each studied gene was normalized using the amplification of three housekeeping genes, Gapdh (glyceraldehyde-3-phosphate dehydrogenase), Hprt1 (hypoxanthine guanine phosphoribosyl transferase 1) and Tbp (TATA box binding protein). Data were analyzed using qBase software (Hellemans et al., 2007) .
Measurement of proteasome activity
Proteasome activity was measured in accordance with the protocol described by Kisselev and Goldberg (2005) . Briefly, cells were harvested in a lysis buffer that maintained 26S proteasome integrity. After incubation on ice during 45 min, the cytosols were squeezed out by centrifugation at 14 000 r.p.m. at 4 1C for 15 min. In all, 15 mg of proteins was loaded on opaque-white 96-well plates. Volume was adjusted at 90 ml with 26S proteasome assay buffer. Thereafter, 10 ml of Z-LLVY-AMC (Calbiochem, Damstadt, Germany) at 1 mM stock solution was added and the plate was incubated at 37 1C. Fluorescence was measured after 15 and 30 min using a fluorimeter (Dynatech Laboratories, Chantilly, VA, USA) with excitation at 365 nm wavelength and emission at 450 nm wavelength.
Protein extracts and immunoblot analyses
Cell extracts were prepared using osmotic shock methods as previously described (Loison et al., 2006) . Protein extracts were separated on polyacrylamide gel and transferred to a nitrocellulose membrane (Amersham Bioscience, Little Chalfont, England). Anti-Hsp25 (sc-1084), anti-Hsp70 (SPA-810) and anti-b-actin (A-1978) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), Stressgen (Ann Arbor, MI, USA) and Sigma Aldrich respectively. Antip53 antibody was a gift from Dr T Soussi, Universite´Pierre et Marie Curie, Paris, France.
Pulse-chase assays Wild-type, Hsf1
À/À and Hsf2 À/À iMEFs were washed with phosphate-buffered saline and preincubated for 30 min with methionine-and leucine-free Dulbecco's modified Eagle's medium, containing 10% dialyzed fetal bovine serum and 4 mM glutamine. Cells were labeled for 1 h 30 min in the same medium with 10 mCi/ml of L-[
35 S]methionine (Perkin-Elmer, Courtaboeuf, France), and chased in complete media. At various times after termination of labeling, cells were isolated in phosphate-buffered saline 0.5% Triton X-100 supplemented by protease inhibitors (Roche Applied Science, Meylan, France) and incubated for 30 min on ice. Proteins were immunoprecipitated overnight at 4 1C with 5 mg of monoclonal anti-p53 antibody in phosphate-buffered saline supplemented with NaCl 600 nM, Triton X-100 4% and protease inhibitors (Roche Applied Science). Immune complexes recovered by protein-G sepharose were washed three times with phosphatebuffered saline supplemented with Triton X-100 1% and NaCl 150 mM. Immune complexes were electrophoretically separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. Gels were fixed and dried, and subjected to autoradiography. The corresponding lysates (lysates 35 S) were loaded as control for an equal amount of proteins, as well as for equal incorporation of 35 S.
Conflict of interest
The authors declare no conflict of interest.
